C
CraniUS
A manufacturer of medical equipment
About CraniUS
CraniUS LLC is a pioneering startup based in Baltimore, MD, founded in May 2021 by Dr. Chad Gordon. The company operates in the medical technology (MedTech) sector, focusing on innovative solutions for chronic brain diseases. CraniUS is developing the NeuroPASS device, the first smart, refillable, and fully implantable medical device designed for direct medicine delivery to the brain. This device aims to bypass the blood-brain barrier—a protective shield around the brain that prevents many medications from entering—allowing for more effective and long-term treatment of brain conditions.
The NeuroPASS device is powered by a novel wireless charging system, making it convenient and user-friendly for patients. Currently, the device is in the pre-clinical development stage, meaning it is being tested in labs but is not yet available for commercial use. The company is on the pathway to clinical studies, which are necessary steps before the device can be approved for widespread medical use.
CraniUS primarily serves patients with chronic brain diseases, a market that includes conditions such as Alzheimer's, Parkinson's, and brain tumors. These diseases often require long-term medication management, making the NeuroPASS device a potentially transformative solution. The company’s business model revolves around research and development (R&D), aiming to bring groundbreaking diagnostics and treatments to market. Once the NeuroPASS device is commercially available, CraniUS will generate revenue through the sale of the device and possibly through partnerships with healthcare providers and pharmaceutical companies.
In summary, CraniUS is a MedTech startup focused on developing a revolutionary medical device for direct brain medicine delivery, targeting chronic brain disease patients. The company is still in the R&D phase but has already garnered significant recognition, being named the Top MedTech Startup of 2023 by MedTech Outlook.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Baltimore, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 78.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Neurology, Spinout, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $1.1M | — | National Institutes of Health | ↗ |
| GRANT✓Other financing | Jan 2026 | $1M | — | State of Maryland | ↗ |
Growth signals
Latest recorded traffic for CraniUS is 1.6K monthly website visits, up 45.5% over the last three months. CraniUS's team grew 18.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
State of Maryland
National Institutes of Health
Other known investors4 additional known investors
Johns Hopkins University
Alex J.
Jason Goldsmith
Johns Hopkins Technology Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CraniUS on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CraniUS’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.